Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 199,182,672
  • Shares Outstanding, K 2,365,590
  • Annual Sales, $ 49,436 M
  • Annual Income, $ 6,712 M
  • 36-Month Beta 0.73
  • Price/Sales 4.11
  • Price/Cash Flow 17.69
  • Price/Book 2.85

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.43 +3.61%
on 07/11/17
86.15 -2.07%
on 06/27/17
-1.38 (-1.61%)
since 06/26/17
3-Month
76.60 +10.14%
on 04/28/17
86.90 -2.91%
on 06/22/17
+8.02 (+10.50%)
since 04/26/17
52-Week
66.93 +26.06%
on 12/08/16
86.90 -2.91%
on 06/22/17
+1.35 (+1.63%)
since 07/26/16

Most Recent Stories

More News
What's in Store for Conatus (CNAT) this Earnings Season?

Conatus' (CNAT) aim to progress with its lead candidate emricasan might boost the stock in Q2 results, although the company's current portfolio shows no approved product and revenue generation.

CNAT : 6.08 (-0.16%)
ZTS : 61.66 (+0.62%)
NVS : 84.40 (+0.24%)
TSRO : 130.60 (+1.28%)
Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat

Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.

CELG : 137.31 (+0.64%)
NVS : 84.40 (+0.24%)
AMGN : 176.50 (-2.43%)
SNY : 47.82 (-0.52%)
Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN

Bristol-Myers Squibb Company (BMY), Celgene (CELG) and Alexion Pharma (ALXN) are set to report second-quarter results on Jul 27.

CELG : 137.31 (+0.64%)
JNJ : 131.11 (-0.58%)
MRK : 61.87 (-0.79%)
NVS : 84.40 (+0.24%)
BMY : 56.06 (+0.20%)
ALXN : 130.79 (+1.11%)
BIIB : 296.75 (+4.87%)
Novartis selects Cryoport to support CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia

Life sciences company Cryoport (Nasdaq:CYRX) (Nasdaq:CYRXW) said on Tuesday that it has entered into an initial three-year term for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy with Novartis....

CYRXW : 3.45 (+18.97%)
CYRX : 6.73 (+4.66%)
NVS : 84.40 (+0.24%)
Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK

We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.

JNJ : 131.11 (-0.58%)
LLY : 81.33 (-1.05%)
VRTX : 164.01 (+1.26%)
NVS : 84.40 (+0.24%)
GILD : 74.20 (+0.62%)
GSK : 40.97 (-2.36%)
BIIB : 296.75 (+4.87%)
Ophthalmic Drugs Market to Reach US$34.3 Billion by 2025: Players Entering Into Co-development Agreements to Enhance Product Portfolio

ALBANY, New York, July 25, 2017 /PRNewswire/ --

VRX.TO : 22.48 (+1.44%)
BAYRY : 130.0300 (+0.02%)
AERI : 54.85 (-1.97%)
SNPHF : 13.2500 (-0.69%)
AGN : 255.22 (+0.24%)
NVS : 84.40 (+0.24%)
REGN : 517.01 (+0.69%)
PFE : 32.88 (-0.66%)
Bioengineered Protein Drugs Market Worth US$336.9 Billion by 2025: Increasing Drugs in Phase III of Clinical Trials to Boost the Market

Some of the prominent participants in the global bioengineered protein drugs market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Amgen, Inc., Bayer AG, Merck & Co., Inc., Dr. Reddy's Laboratories...

BAYRY : 130.0300 (+0.02%)
ABT : 50.41 (-0.83%)
JNJ : 131.11 (-0.58%)
MRK : 61.87 (-0.79%)
LLY : 81.33 (-1.05%)
NVS : 84.40 (+0.24%)
AMGN : 176.50 (-2.43%)
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries

Novartis International AG / Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries . Processed and transmitted by Nasdaq Corporate Solutions. The...

NVS : 84.40 (+0.24%)
Foreign Stock Roundup: ABB, Novartis Beat on Earnings

Global markets were weighed down by comments from the ECB and Bank of Japan even as bullish GDP data emerged from China this week

ABB : 23.28 (-0.81%)
SAP : 104.75 (+0.85%)
ERIC : 6.28 (-1.10%)
CPYYY : 10.6500 (+0.09%)
NVS : 84.40 (+0.24%)
AMX : 17.79 (+0.17%)
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN

Three pharma giants are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.

JNJ : 131.11 (-0.58%)
LLY : 81.33 (-1.05%)
NVS : 84.40 (+0.24%)
AMGN : 176.50 (-2.43%)
BIIB : 296.75 (+4.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Support & Resistance

2nd Resistance Point 85.00
1st Resistance Point 84.60
Last Price 84.40
1st Support Level 83.86
2nd Support Level 83.52

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.